瑞思迈 RMD 深 沪
已收盘 09-19 16:00:00 美东时间
273.19
-0.100
-0.04%
华盛通- 最 高274.025
- 今 开272.92
- 成交量 153.62万股
- 最 低 271.32
- 昨 收 273.29
- 总市值 401.59亿
- 52周最高 293.81
- 市盈率 静 28.74
- 换手率 1.05%
- 52周最低 198.79
- 委 比 -98.24%
- 总股本 1.47亿
- 历史最高 293.81
- 量 比 1.73
- 振 幅 0.99%
- 历史最低 5.65
- 每 手 1
- 风险率 19.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
ResMed Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Analysts' ratings for ResMed (NYSE:RMD) over the last quarter vary from bullish...
09-19 04:00
This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-18 22:00
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
<p>Resmed的董事长兼首席执行官Mick Farrell和首席医疗官Carlos Nunez将在2025年9月23日参加美国银行全球医疗保健会议，并在伦敦当地时间下午1:20左右发表讲话。更多详情和音频网络直播可通过访问<a href="https://investor.resmed.com">https://investor.resmed.com</a>获取。直播结束后24小时内提供回放，有效期为30天。</p> <p>Resmed致力于通过创新技术改善全球140个国家人们的睡眠和呼吸健康，提供个性化的家庭医疗解决方案。投资者可联系+1 858.221.3304或<mailto:investorrelations@Resmed.com>，媒体请联系+1 619.510.1281或<mailto:news@resmed.com>。</p>
09-16 20:05
Resmed Inc Announces Proposed Sale of Securities by Officer
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:R...
09-09 06:58
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
Resmed launched Sleep Institute, a global initiative to advance sleep health science and address undiagnosed sleep disorders, particularly obstructive sleep apnea (OSA). The institute aims to provide evidence-based insights to improve diagnosis, treatment, and policy. With 1 billion people affected by OSA and 852 million experiencing insomnia, Sleep Institute seeks to fill care gaps through research, data sharing, and global collaborations. At th...
09-03 20:15
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
A new study published in *The Lancet Respiratory Medicine* predicts a significant rise in obstructive sleep apnea (OSA) in the U.S. over the next 30 years, driven by aging and rising BMI. By 2050, OSA could affect nearly 77 million adults, a 35% increase from 2020, with a 65% rise among women. The research underscores the need for earlier diagnosis, prevention, and targeted care to address this growing public health challenge.
08-27 13:00
ResMed Director Executes Strategic Stock Transactions
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:R...
08-27 06:57
ResMed CEO Acquires Performance-Based Stock Units
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:R...
08-27 06:57
Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
Resmed's AirTouch N30i nasal mask won two Red Dot Design Awards, recognizing its innovative design and medical excellence. The mask features Resmed's ComfiSoft fabric cushion and a breathable, layered design, offering enhanced comfort and effectiveness for CPAP therapy. Designed with patient experience in mind, it promotes better adherence to treatment, addressing a global health issue affecting over one billion people. Winning both the Red Dot a...
08-21 13:00
